Cancer-associated IDH1/2 mutations lead to the loss of the enzyme’s normal catalytic activity and gain neomorphic activity of reducing αKG to (R)-2-hydroxyglutarate (2-HG), which can be detected at high levels in gliomas and AML patients harboring these mutations9,10. The gene discussed is IDH1; the disease is cancer.